Healthcare
Valeo Pharma Inc.(VPHIF)
Live Price
Offline$0.0001
+0.00% today
1Y Change
-99.79%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +94.3%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Valeo Pharma Inc. (VPHIF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.8% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +94.3%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue +94.3%, EPS 0.0%, free cash flow +40.0% with operating margin -32.0% and ROIC -67.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VPHIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+94.3% vs +7.6% peer median
Operating Margin
Below sector median
-32.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is +94.3% and EPS is 0.0%, while operating margin sits near -32.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 12, 2026 | โ | โ | โ | โ |
2026 Mar 25, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 10, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VPHIF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VPHIF Max Drawdown
-99.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VPHIF and SPY.
Company Overview
Valeo Pharma Inc.
Other OTC
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
- Leadership
- Kyle Steiger
- IPO Date
- Sep 23, 2020
- Employees
- 70
- Street Address
- 16667 Hymus Boulevard
- Mailing
- Kirkland, QC, H9H 4R9
- Region
- Kirkland, QC, CA
- Reporting Currency
- USD
- Investor Line
- 514-694-0150
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- +94.3%
- EPS
- 0.0%
- Free Cash Flow
- +40.0%
Profitability
- Gross Margin
- 24.3%
- Operating Margin
- -32.0%
- Net Margin
- -51.6%
- ROE
- 95.6%
- ROIC
- -67.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.25
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.